［1］陶惠明，冷巧云，汪传文，等.18613例急诊科患者流行病学特点及疾病谱构成［J］. 创伤与急诊电子杂志， 2013， 11(4):32-36.
［2］黄树青，满达，巴特金，等. 呼和浩特市2016年院前急救患者疾病谱分布及流行病学特点:附28325例病例报告［J］. 中华危重病急救医学， 2018， 30(1): 78-82.
［3］于启林，朱士俊，梁爱萍，等.82598例急诊患者疾病分类调查［J］. 中华医院管理杂志， 2001， 17(10): 599-601.
［4］陈晓军，邓秀莲，邱遂虹，等. “120”急救中心院前急救疾病种类及发生月份和区域分布分析［J］. 中国医药， 2017， 12(2):264-267.［5］张在其，陈文标，陈玮莹，等. 广州市97 823例院前急救患者流行病学分析［J］.中国危重病急救医学， 2011， 23(2): 99-103.
［6］陈唯，梁永晴，张湛，等.46336例老年患者院前急救流行病学分析［J］. 中国卫生统计， 2017， 34(4): 629-631.
［7］中华医学会呼吸病学分会《雾化吸入疗法在呼吸疾病中的应用专家共识》制定专家组. 雾化吸入疗法在呼吸疾病中的应用专家共识［J］. 中华医学杂志， 2016， 96(34): 2696-2708.
［8］申昆玲，邓力，李云珠，等. 糖皮质激素雾化吸入疗法在儿科应用的专家共识(2018年修订版)［J］.临床儿科杂志， 2018， 36(2): 95-107.
［9］中国医师协会急诊医师分会，中国人民解放军急救医学专业委员会，北京急诊医学会，等. 雾化吸入疗法急诊临床应用专家共识(2018)［J］.中国急救医学， 2018， 38(7): 565-574.
［10］中华医学会呼吸病学分会哮喘学组，中国哮喘联盟. 支气管哮喘急性发作评估及处理中国专家共识［J］.中华内科杂志， 2018， 57(1): 4-14.
［11］慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组. 慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(2017年更新版)［J］.国际呼吸杂志， 2017， 37(14): 1041-1057.
［12］Chen AH, Zeng GQ, Chen RC, et al. Effects of nebulized high-dose budesonide on moderate-to-severe acute exacerbation of asthma in children: a randomized, double-blind, placebo-controlled study［J］. Respiratory, 2013, 18（Suppl 3）: 47-52.
［13］Hashemian SM, Mortaz E, Jamaati H, et al.Budesonide facilitates weaning from mechanical ventilation in difficult-to-wean very severe COPD patients: Association with inflammatory mediators and cells［J］. J Crit Care, 2018, 44: 161-167.
［14］Akcora B, Celikkaya ME, Ozer C, et al.Bronchoscopy for foreign body aspiration and effects of nebulized albuterol and budesonide combination［J］. Pak J Med Sci, 2017, 33(1): 81-85.
［15］Upham BD, Mollen CJ, Scarfone RJ, et al.Nebulized budesonide added to standard pediatric emergency department treatment of acute asthma: a randomized, double-blind trial［J］. Acad Emerg Med, 2011, 18(7): 665-673.
［16］陈秋萍，周瑞芳，张亚明，等. 全身激素联合吸入激素治疗急性喉炎疗效观察［J］.中华耳鼻咽喉头颈外科杂志， 2018， 53(1): 53-56.［17］Ke H, Li ZK, Yu XP,et al. Efficacy of different preparations of budesonide combined with pulmonary surfactant in the treatment of neonatal respiratory distress syndrome: a comparative analysis［J］.Zhongguo Dang Dai Er Ke Za Zhi, 2016, 18(5): 400-404.
［18］Yilmazel Ucar E, Araz O, Meral M, et al. Two different dosages of nebulized steroid versus parenteral steroid in the management of COPD exacerbations: a randomized control trial［J］. Med Sci Monit, 2014, 20: 513-520.
［19］Gunen H, Hacievliyagil SS, Yetkin O, et al. The role of nebulized budesonide in the treatment of exacerbations of COPD［J］. Eur Respir J, 2007, 29(4): 660-667.
［20］Mirici A, Meral M, Akgun M. Comparison of the efficacy of nebulized budesonide with parenteral corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease［J］. Clin Drug Investig, 2003, 23(1): 55-62.
［21］Kashefi P, Abbasi A, Abbasi M, et al. Comparison of the efficacy of nebulized budesonide and intravenous dexamethasone administration before extubation in prevention of post-extubation complications among patients admitted in intensive care unit［J］. Adv Biomed Res, 2015, 4: 11.
［22］Sun X, He Z, Zhang J, et al. Compare the efficacy of inhaled budesonide and systemic methylprednisolone on systemic inflammation of AECOPD［J］. Pulm Pharmacol Ther, 2015, 31: 111-116.
［23］Ding Z, Li X, Lu Y, et al. A randomized, controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment on acute exacerbation of chronic obstructive pulmonary disease［J］. Respir Med, 2016, 121: 39-47.
［24］于学忠.协和急诊医学［M］.北京:科学出版社, 2010: 639.
［25］Devidayal, Singhi S, Kumar L, et al. Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma［J］. Acta Paediatr, 1999, 88(8): 835-840.
